Abstract:Jennifer Green Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC, USA Correspondence: Jennifer Green, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC, USA, Email This article discusses innovations, advancements, and discoveries in continuous glucose monitoring (CGM) that were presented at the European Association for the Study of Diabetes 2024 Conference in Madrid, Spain, held in September 2024. Specifically, the author will discuss data from studies that discuss the impact of CGM on hemoglobin A1C in people with type 2 diabetes; the impact of CGM use in hospitalization settings for people with diabetes; the effectiveness of CGM in those who have undergone cardiac surgery; the efficacy of real-time CGM in adults hospitalized with diabetic ketoacidosis; time in rage in older individuals; and new devices for glucose sensing. Keywords: continuous glucose monitoring, CGM, diabetic ketoacidosis, DKA, hemoglobin A1c, hospitalization, hypoglycemia, hyperglycemia, primary care, real-world evidence, cardiac surgery, type 2 diabetes This Podcast was sponsored by Springer Healthcare. 00:35 . Hello everyone, you are listening to a Podcast to Practice, brought to you by Springer Health Care IME. Podcast to Practice brings you expert-led, independent, medical educations discussions, inspiring healthcare professionals to maximise their learning and make measurable changes in their own clinical practice. This podcast is part of an independent medical education programme entitled "Techniques for implementing continuous glucose monitoring in primary care" and supported by an independent education grant from Abbott. 01:09 . My name is Jennifer Green, and I am an endocrinologist and professor of medicine at Duke University in Durham, North Carolina. I'd like to welcome you to this independent medical education program on CGM device updates, in which I will share with you some of the exciting innovations, advancements, and discoveries in continuous glucose monitoring, or CGM, that were presented at the European Association for the Study of Diabetes, or EASD, 2024 annual meeting held in Madrid, Spain, between September 9 and 13 of 2024. The good news is that there were many intriguing sessions on CGM usage and CGM data at EASD this year. But, for today, I will focus on just a few key sessions which in particular I feel are most likely to impact your practice. Numerous of these presentations further explored the effects of CGM use in people with Type 2 diabetes, treated with or without insulin; assessed the efficacy and utility of CGM use in hospitalized individuals with diabetes; defined the correlation between various CGM glucose parameters and the risk of diabetes complications or pregnancy outcomes in Type 1 diabetes; and also gave us a glimpse into what the future of CGM devices is likely to be. So I am going to start with some of the information and data from studies assessing the impact of CGM use in people with Type 2 diabetes, who were either on or not on insulin therapy as part of their diabetes management regimen. The first was presented by Dr Bergenstal from the International Diabetes Center in the US and was described The Impact of Continuous Glucose Monitoring on Hemoglobin A1C in People with Type 2 Diabetes. 1 And this was a real-world analysis of the impact of CGM on haemoglobin A1C within a broad Type 2 diabetes population in the United States with and without the use of insulin therapy. And the authors decided to study this because there just was not much data, particularly regarding the impact of CGM use in people not using insulin. So they used the Optum de-identified Market Clarity Database, which has information on nearly 80 million individuals, and they performed a retrospective analysis on that group of individuals and identified a subgroup of about 6,000 patients who were continually involved in their health plan, and who had haemoglobin A1C values during the time periods of interest and were treated with non-insulin medicines, basal insulin, or prandial insulin therapy. So these individuals would have started a CGM for the first time between June of 2019 and January of 2022. And what they found when they looked at the outcomes in this group of 6,000 people was that haemoglobin A1C values decreased by 0.9% at about 3 months after starting CGM in the people who were not on insulin, were on basal insulin alone, or were on prandial insulin therapy. And this was all considered to be significant. The haemoglobin A1Cs also remained lower in those three groups throughout the 12 months of follow up, generally ranging between 1% and 1.1% lower than baseline, again, all being significant differences from baseline. So those haemoglobin A1C improvements were -Abstract Truncated-

Student Pharmacist Counseling Performance after Hands-on Continuous Glucose Monitoring Education: A Multi-institutional Pragmatic Randomized Study

"Life with Diabetes": A Pilot Study on an Experiential Continuous Glucose Monitoring Curriculum for Resident Physicians

A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes

Evaluation of a pharmacist-led personal continuous glucose monitor workflow to improve glycemic management in an internal medicine clinic

Health literacy of patients using continuous glucose monitoring

Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring

Adding a Brief Continuous Glucose Monitoring Intervention to the National Diabetes Prevention Program: A Multimethod Feasibility Study

Twelve-month psychosocial outcomes of continuous glucose monitoring with behavioural support in parents of young children with type 1 diabetes

The effectiveness of continuous glucose monitoring with remote telemonitoring-enabled virtual educator visits in adults with non-insulin dependent type 2 diabetes: A randomized trial

Continuous glucose monitoring for primary care patients with diabetes: Barriers, facilitators, & resources to support access

A Team-Based Training for Continuous Glucose Monitoring in Diabetes Care: Mixed Methods Pilot Implementation Study in Primary Care Practices

Development of a Theoretical Continuous Glucose Monitoring Module for Pharmacy Students: Preparing Pharmacists for the Future

980-P: Continuous Glucose Monitor Improves Glycemic Control in Youth-Onset Type 2 Diabetes

Continuous glucose monitoring among nurse practitioners in primary care: Characteristics associated with prescribing and resources needed to support use

Mixed methods study on the feasibility of implementing periodic continuous glucose monitoring among individuals with type 2 diabetes mellitus in a primary care setting

647-P: Improved Glycemic Control and Continuous Glucose Monitoring (CGM) Utilization: A Comparison of Real-Time CGM and Intermittent Scanning CGM

Feasibility and Performance of Continuous Glucose Monitoring to Guide Computerized Insulin Infusion Therapy in Cardiovascular Intensive Care Unit

Empowering Hospitalized Patients With Diabetes: Implementation of a Hospital-wide CGM Policy With EHR-Integrated Validation for Dosing Insulin

Continuous Glucose Monitoring-Guided Insulin Administration in Long-Term Care Facilities: A Randomized Clinical Trial

Techniques for Implementing Continuous Glucose Monitoring in Primary Care: Key CGM Updates and Highlights from the EASD2024 Conference

Exploring the Initial Encounter with Continuous Glucose Monitoring among Individuals with Type 2 Diabetes: A Two-Week Trip